A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

Joanne Quan(Roche (Switzerland)), Michael W. Konstan(Roche (Switzerland)), Judy P. Sy(Roche (Switzerland)), Philip Robinson(Roche (Switzerland)), Harm A.W.M. Tiddens(Radboud University Nijmegen), Mary Ellen B. Wohl(Roche (Switzerland)), Mark Montgomery(Roche (Switzerland)), Sheila G. McKenzie(Roche (Switzerland))
The Journal of Pediatrics
December 1, 2001
10.1067/mpd.2001.118570
Cited by 302

Related Papers

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation
|New England Journal of Medicine|2010|802
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation
|Thorax|2011|496
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
|The Lancet Respiratory Medicine|2014|442
Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis
|The Journal of Pediatrics|2007|441